Roche bets big on America: $50bn to fuel next-gen weight loss drugs and diagnostics boom
Discover how Roche’s $50 billion U.S. investment is transforming pharma R&D, diagnostics, and job creation across eight states and reshaping global exports. Read More
Recursion Pharmaceuticals’ stock plunges 7% after shock Q4 loss – What went wrong?
Recursion Pharmaceuticals, a clinical-stage biotechnology company leveraging artificial intelligence for drug discovery, reported a significantly wider loss for the fourth quarter of 2024. The company’s ... Read More
FDA approves Genentech’s Evrysdi tablet as first SMA treatment in tablet form
In a significant development for the treatment of spinal muscular atrophy (SMA), the U.S. Food and Drug Administration (FDA) has approved Genentech’s Evrysdi tablet, marking ... Read More
Roche’s Gazyva shows superior efficacy in lupus nephritis treatment, Phase III trial data reveals
Roche has announced promising new data from its phase III REGENCY clinical trial, published in the New England Journal of Medicine, highlighting the superior efficacy ... Read More
Cancer treatment just got faster: FDA approves Genentech’s Tecentriq Hybreza for quick 7-minute injection
The U.S. Food and Drug Administration (FDA) has granted approval for Tecentriq Hybreza, the first and only PD-(L)1 inhibitor for subcutaneous injection, developed by Genentech, ... Read More
Genentech announces reintroduction of Susvimo for Wet AMD treatment in US
Genentech, a key member of the Roche Group, has officially announced the reintroduction of Susvimo (ranibizumab injection) 100 mg/mL, a cutting-edge treatment for wet, or ... Read More
FDA approves Genentech’s Vabysmo prefilled syringe for eye diseases
In a significant advancement in the treatment of eye diseases, the U.S. Food and Drug Administration (FDA) has approved Genentech's Vabysmo (faricimab-svoa) 6.0 mg single-dose ... Read More
Lonza to acquire Genentech’s biologics manufacturing facility in Vacaville for $1.2bn
In a strategic move that significantly escalates its capacity in the biologics manufacturing landscape, Lonza, a key global player in manufacturing for the pharmaceutical, biotech, ... Read More
FDA approves Genentech’s Xolair for food allergies: A new horizon in allergy treatment
The U.S. Food and Drug Administration (FDA) has approved Xolair (omalizumab) for reducing allergic reactions, including anaphylaxis, that may occur with accidental exposure to foods ... Read More
Genentech’s Phase 3 study of inavolisib in breast cancer reveals positive results
Genentech, part of the Roche Group, has presented compelling results from the Phase III INAVO120 study, evaluating the effectiveness of inavolisib in combination with palbociclib ... Read More